A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis

Inclusion Criteria: * Male or female patients (Non-pregnant) of plaque psoriasis aged 18 to 65 years having either Fitzpatrick skin type I-III or IV-VI.\<br/\> * Diagnosis of stable plaque psoriasis for 6 month by a dermatologist with lesions on arms, legs or trunk. * Mild to moderate psoriasis on Physician's global assessment (PGA), * Body Surface Area (BSA) involvement of 5-10% (both included) and PASI ≥ 5. * Patients must be willing to provide written informed consent and willing to comply with study requirements Exclusion Criteria: * Predominantly palmo-plantar, flexural, scalp and nail location of psoriasis * Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis. * Patient with any uncontrolled systemic disease * Patient with positive serology tests like HIV, HCV \& HBsAg. * Patient with presence of any skin disease that might interfere with the diagnosis or evaluation of the test medications. * Patient with spontaneously improving or rapidly deteriorating plaque psoriasis. * Use of systemic agents within four weeks prior to screening. * Use of biologic agents within four weeks prior to study entry. * Use of topical drugs that might alter the course of psoriasis or has received ultraviolet B treatment within two weeks prior to study entry. * Use of phototherapy with psoralen ultraviolet A treatment within four weeks prior to study entry. * Known sensitivity to any of the study treatments and/or study treatment's components. * Need for surgery or hospitalization during the study * Pregnant or nursing Female patient or planning a pregnancy * Concurrent involvement in any other clinical study within 30 days prior to entering the study